191 related articles for article (PubMed ID: 35452014)
1. Usefulness of 68 Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome.
Ding J; Tong A; Hacker M; Feng M; Huo L; Li X
Clin Nucl Med; 2022 Aug; 47(8):669-676. PubMed ID: 35452014
[TBL] [Abstract][Full Text] [Related]
2. Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using
Ding J; Tong A; Zhang Y; Wen J; Zhang H; Hacker M; Huo L; Li X
J Nucl Med; 2022 Mar; 63(3):368-375. PubMed ID: 34301781
[TBL] [Abstract][Full Text] [Related]
3. CXCR4-Directed PET/CT with [
Chen Z; Yang A; Zhang J; Chen A; Zhang Y; Huang C; Chen S; Yao S; Miao W
Mol Imaging Biol; 2022 Jun; 24(3):416-424. PubMed ID: 34651291
[TBL] [Abstract][Full Text] [Related]
4. Imaging CXCR4 receptors expression for staging multiple myeloma by using
Shekhawat AS; Singh B; Malhotra P; Watts A; Basher R; Kaur H; Hooda M; Radotra BD
Br J Radiol; 2022 Aug; 95(1136):20211272. PubMed ID: 35731811
[TBL] [Abstract][Full Text] [Related]
5. Imaging Inflammation in Atherosclerosis with CXCR4-Directed
Kircher M; Tran-Gia J; Kemmer L; Zhang X; Schirbel A; Werner RA; Buck AK; Wester HJ; Hacker M; Lapa C; Li X
J Nucl Med; 2020 May; 61(5):751-756. PubMed ID: 31653710
[TBL] [Abstract][Full Text] [Related]
6. [
Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
[TBL] [Abstract][Full Text] [Related]
7. High-resolution(18)F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease.
Chittiboina P; Montgomery BK; Millo C; Herscovitch P; Lonser RR
J Neurosurg; 2015 Apr; 122(4):791-7. PubMed ID: 25479121
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of [ 68 Ga]Ga-Pentixafor PET/CT in malignant melanoma: a pilot study.
Manafi-Farid R; Mahini M; Mirshahvalad SA; Fallahi B; Fard-Esfahani A; Emami-Ardekani A; Eftekhari M; Mousavi SA; Beiki D
Nucl Med Commun; 2024 Mar; 45(3):221-228. PubMed ID: 38214076
[TBL] [Abstract][Full Text] [Related]
9. CXCR4-directed [
Chaman Baz AH; van de Wiel E; Groenewoud H; Arntz M; Gotthardt M; Deinum J; Langenhuijsen J
BMJ Open; 2022 Aug; 12(8):e060779. PubMed ID: 35998969
[TBL] [Abstract][Full Text] [Related]
10. Clinical Value of
Ding J; Li X; Liu S; Gao Y; Zheng G; Hacker M; Zhang Y; Tong A; Huo L
J Nucl Med; 2024 Jan; 65(1):117-124. PubMed ID: 38050127
[TBL] [Abstract][Full Text] [Related]
11.
Luo Y; Cao X; Pan Q; Li J; Feng J; Li F
J Nucl Med; 2019 Dec; 60(12):1724-1729. PubMed ID: 31101745
[No Abstract] [Full Text] [Related]
12. Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [
Kosmala A; Duell J; Schneid S; Serfling SE; Higuchi T; Weich A; Lapa C; Hartrampf PE; Raderer M; Einsele H; Buck AK; Topp MS; Schlötelburg W; Werner RA
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):749-755. PubMed ID: 37943339
[TBL] [Abstract][Full Text] [Related]
13. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.
Lapa C; Lückerath K; Kleinlein I; Monoranu CM; Linsenmann T; Kessler AF; Rudelius M; Kropf S; Buck AK; Ernestus RI; Wester HJ; Löhr M; Herrmann K
Theranostics; 2016; 6(3):428-34. PubMed ID: 26909116
[TBL] [Abstract][Full Text] [Related]
14. The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism.
Zheng Y; Long T; Peng N; Zhen M; Ye Q; Zhang Z; He Y; Chen Z; Gan Y; Luo M; Li C; Liu Z; Guo M; Wang M; Luo X; Hu S; Liu L; Jiang T
J Clin Endocrinol Metab; 2023 Dec; 109(1):171-182. PubMed ID: 37477496
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT.
Bouter Y; Meller B; Sahlmann CO; Wolf BJ; Langer L; Bankstahl JP; Wester HJ; Kropf S; Meller J; Bouter C
Nuklearmedizin; 2018 Sep; 57(5):198-203. PubMed ID: 30267402
[TBL] [Abstract][Full Text] [Related]
16. Development of
Shukla J; Vatsa R; Walia R; Chhabra A; Rana N; Singh H; Kumar R; Mittal BR
Cancer Biother Radiopharm; 2021 Oct; 36(8):642-650. PubMed ID: 34191604
[No Abstract] [Full Text] [Related]
17. [Preliminary study on the ability of
Gao YJ; Ding J; Cui YY; Li TY; Zhang YS; Huo L; Tong AL
Zhonghua Nei Ke Za Zhi; 2023 Mar; 62(3):267-271. PubMed ID: 36822852
[No Abstract] [Full Text] [Related]
18. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
[TBL] [Abstract][Full Text] [Related]
19. Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach.
Linde P; Baues C; Wegen S; Trommer M; Quaas A; Rosenbrock J; Celik E; Marnitz S; Bruns CJ; Fischer T; Schomaecker K; Wester HJ; Drzezga A; van Heek L; Kobe C
Cancer Imaging; 2021 Feb; 21(1):22. PubMed ID: 33579381
[TBL] [Abstract][Full Text] [Related]
20. 68 Ga-Pentixafor PET/CT for In Vivo Imaging of CXCR4 Receptors in Glioma Demonstrating a Potential for Response Assessment to Radiochemotherapy: Preliminary Results.
Waheed A; Singh B; Watts A; Kaur H; Singh H; Dhingra K; Ahuja C; Madan R; Singh A; Radotra BD
Clin Nucl Med; 2024 Apr; 49(4):e141-e148. PubMed ID: 38350065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
